6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
after	IN	after	after	after	N	O
premature	JJ	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

?	.	?	?	?	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
[	JJ	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

?	.	?	?	?	N	O

Spinal	JJ	spinal	spinal	spinal	N	O
epidural	JJ	epidural	epidural	epidur	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
puncture	NN	puncture	puncture	punctur	N	O
[	JJ	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Bristol	NNP	bristol	bristol	bristol	N	O
-	:	-	-	-	N	O
Myers	NNS	myers	myers	myer	N	O
Squibb	VBP	squibb	squibb	squibb	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
721	CD	721	721	721	N	O
-	:	-	-	-	N	O
5072	CD	5072	5072	5072	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Reduction	NN	reduction	reduction	reduct	N	O

of	IN	of	of	of	N	O
Risk	NNP	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Stroke	NNP	stroke	stroke	stroke	Y	O
and	CC	and	and	and	N	O
Systemic	NNP	systemic	systemic	system	N	O
Embolism	NNP	embolism	embolism	embol	Y	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Nonvalvular	NNP	nonvalvular	nonvalvular	nonvalvular	N	O
Atrial	NNP	atrial	atrial	atrial	N	O
Fibrillation	NNP	fibrillation	fibrillation	fibril	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
and	CC	and	and	and	N	O
AVERROES	NNP	averroes	averroes	averro	N	O
studies	NNS	studies	study	studi	N	O
[	NNP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NNS	)]	)]	)]	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
11	CD	11	11	11	N	O
,	,	,	,	,	N	O
284	CD	284	284	284	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
and	CC	and	and	and	N	O
602	CD	602	602	602	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
exposure	NN	exposure	exposure	exposur	N	O
was	VBD	was	wa	wa	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
9375	CD	9375	9375	9375	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
24	CD	24	24	24	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
3369	CD	3369	3369	3369	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
was	VBD	was	wa	wa	N	O
89	CD	89	89	89	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
AVERROES	NNP	averroes	averroes	averro	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
59	JJ	59	59	59	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
3000	CD	3000	3000	3000	N	O
patient	NN	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reason	NN	reason	reason	reason	N	O
for	IN	for	for	for	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
for	IN	for	for	for	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
;	:	;	;	;	N	O
in	IN	in	in	in	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
this	DT	this	this	thi	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
and	CC	and	and	and	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
and	CC	and	and	and	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
AVERROES	NNP	averroes	averroes	averro	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
and	CC	and	and	and	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
on	IN	on	on	on	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
and	CC	and	and	and	N	O
aspirin	NN	aspirin	aspirin	aspirin	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Nonvalvular	NNP	nonvalvular	nonvalvular	nonvalvular	N	O
Atrial	NNP	atrial	atrial	atrial	N	O
Fibrillation	NNP	fibrillation	fibrillation	fibril	Y	O
in	IN	in	in	in	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
and	CC	and	and	and	N	O
AVERROES	NNP	averroes	averroes	averro	N	O

Tables	NNS	tables	table	tabl	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
show	VBP	show	show	show	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
rate	NN	rate	rate	rate	N	O
(	(	(	(	(	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
event	NN	event	event	event	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
and	CC	and	and	and	N	O
AVERROES	NNP	averroes	averroes	averro	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Bleeding	JJ	bleeding	bleeding	bleed	Y	B-AdverseReaction
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Nonvalvular	NNP	nonvalvular	nonvalvular	nonvalvular	N	O
Atrial	NNP	atrial	atrial	atrial	N	O
Fibrillation	NNP	fibrillation	fibrillation	fibril	Y	O
in	IN	in	in	in	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O

ELIQUISN	NN	eliquisn	eliquisn	eliquisn	N	O
9088	CD	9088	9088	9088	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
pt	NN	pt	pt	pt	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
)	)	)	)	)	N	O
WarfarinN	IN	warfarinn	warfarinn	warfarinn	N	O
9052	CD	9052	9052	9052	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
pt	NN	pt	pt	pt	N	O
-	:	-	-	-	N	O
year	NN	year	year	year	N	O
)	)	)	)	)	N	O
Hazard	NNP	hazard	hazard	hazard	N	O
Ratio	NNP	ratio	ratio	ratio	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
)	)	)	)	)	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
value	NN	value	value	valu	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction

events	NNS	events	event	event	N	O
within	IN	within	within	within	N	O
each	DT	each	each	each	N	O
subcategory	NN	subcategory	subcategory	subcategori	N	O
were	VBD	were	were	were	N	O
counted	VBN	counted	counted	count	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
subject	NN	subject	subject	subject	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
subjects	NNS	subjects	subject	subject	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
contributed	VBN	contributed	contributed	contribut	N	O
events	NNS	events	event	event	N	O
to	TO	to	to	to	N	O
multiple	JJ	multiple	multiple	multipl	N	O
endpoints	NNS	endpoints	endpoint	endpoint	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
counted	VBN	counted	counted	count	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
or	CC	or	or	or	N	O
within	IN	within	within	within	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
stopping	VBG	stopping	stopping	stop	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
overt	JJ	overt	overt	overt	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
of	IN	of	of	of	N	O
2	CD	2	2	2	N	B-Severity
g	NN	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
transfusion	NN	transfusion	transfusion	transfus	Y	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
packed	JJ	packed	packed	pack	N	O
red	JJ	red	red	red	N	O
blood	NN	blood	blood	blood	N	O
cells	NNS	cells	cell	cell	N	O
,	,	,	,	,	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
a	DT	a	a	a	N	I-AdverseReaction
critical	JJ	critical	critical	critic	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
:	:	:	:	:	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	I-AdverseReaction
,	,	,	,	,	N	O
intraspinal	JJ	intraspinal	intraspinal	intraspin	N	I-AdverseReaction
,	,	,	,	,	N	O
intraocular	JJ	intraocular	intraocular	intraocular	N	I-AdverseReaction
,	,	,	,	,	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	I-AdverseReaction
,	,	,	,	,	N	O
intra	JJ	intra	intra	intra	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
articular	NN	articular	articular	articular	N	I-AdverseReaction
,	,	,	,	,	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	I-AdverseReaction
with	IN	with	with	with	N	O
compartment	JJ	compartment	compartment	compart	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
retroperitoneal	NN	retroperitoneal	retroperitoneal	retroperiton	N	I-AdverseReaction
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	I-AdverseReaction
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
bleed	NN	bleed	bleed	bleed	N	I-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
intracerebral	JJ	intracerebral	intracerebral	intracerebr	N	B-AdverseReaction
,	,	,	,	,	N	O
intraventricular	JJ	intraventricular	intraventricular	intraventricular	N	B-AdverseReaction
,	,	,	,	,	N	O
subdural	JJ	subdural	subdural	subdur	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
subarachnoid	JJ	subarachnoid	subarachnoid	subarachnoid	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
.	.	.	.	.	N	O

Any	DT	any	any	ani	N	O
type	NN	type	type	type	N	O
of	IN	of	of	of	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
stroke	NN	stroke	stroke	stroke	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
adjudicated	VBN	adjudicated	adjudicated	adjud	N	O
and	CC	and	and	and	N	O
counted	VBN	counted	counted	count	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
major	JJ	major	major	major	N	B-Severity
bleed	NN	bleed	bleed	bleed	N	I-AdverseReaction
.	.	.	.	.	N	O

S	NN	s	s	s	N	O
On	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
analysis	NN	analysis	analysis	analysi	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
ITT	NNP	itt	itt	itt	N	O
analysis	NN	analysis	analysis	analysi	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Section	NN	section	section	section	N	O
14	CD	14	14	14	N	O
.	.	.	.	.	N	O

GI	NNP	gi	gi	gi	N	B-AdverseReaction
bleed	VBD	bleed	bleed	bleed	N	I-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
GI	NNP	gi	gi	gi	N	I-AdverseReaction
,	,	,	,	,	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
GI	NNP	gi	gi	gi	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rectal	JJ	rectal	rectal	rectal	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
an	DT	an	an	an	N	O
adjudicated	JJ	adjudicated	adjudicated	adjud	N	O
death	NN	death	death	death	Y	B-AdverseReaction
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
primary	JJ	primary	primary	primari	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
as	IN	as	a	as	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
or	CC	or	or	or	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
intracranial	JJ	intracranial	intracranial	intracrani	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	O

327	CD	327	327	327	N	O
(	(	(	(	(	N	O
2.13	CD	2.13	2.13	2.13	N	O
)	)	)	)	)	N	O
462	CD	462	462	462	N	O
(	(	(	(	(	N	O
3.09	CD	3.09	3.09	3.09	N	O
)	)	)	)	)	N	O
0.69	CD	0.69	0.69	0.69	N	O
(	(	(	(	(	N	O
0.60	CD	0.60	0.60	0.60	N	O
,	,	,	,	,	N	O
0.80	CD	0.80	0.80	0.80	N	O
)	)	)	)	)	N	O
0.0001	CD	0.0001	0.0001	0.0001	N	O

Intracranial	NNP	intracranial	intracranial	intracrani	N	O
(	(	(	(	(	N	O
ICH	NNP	ich	ich	ich	N	B-AdverseReaction
)	)	)	)	)	N	O
?	.	?	?	?	N	O

52	CD	52	52	52	N	O
(	(	(	(	(	N	O
0.33	CD	0.33	0.33	0.33	N	O
)	)	)	)	)	N	O
125	CD	125	125	125	N	O
(	(	(	(	(	N	O
0.82	CD	0.82	0.82	0.82	N	O
)	)	)	)	)	N	O
0.41	CD	0.41	0.41	0.41	N	O
(	(	(	(	(	N	O
0.30	CD	0.30	0.30	0.30	N	O
,	,	,	,	,	N	O
0.57	CD	0.57	0.57	0.57	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Hemorrhagic	NNP	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
strokeS	VBD	strokes	stroke	stroke	N	I-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
0.24	CD	0.24	0.24	0.24	N	O
)	)	)	)	)	N	O
74	CD	74	74	74	N	O
(	(	(	(	(	N	O
0.49	CD	0.49	0.49	0.49	N	O
)	)	)	)	)	N	O
0.51	CD	0.51	0.51	0.51	N	O
(	(	(	(	(	N	O
0.34	CD	0.34	0.34	0.34	N	O
,	,	,	,	,	N	O
0.75	CD	0.75	0.75	0.75	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Other	JJ	other	other	other	N	O
ICH	NNP	ich	ich	ich	N	B-AdverseReaction
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
0.10	CD	0.10	0.10	0.10	N	O
)	)	)	)	)	N	O
51	CD	51	51	51	N	O
(	(	(	(	(	N	O
0.34	CD	0.34	0.34	0.34	N	O
)	)	)	)	)	N	O
0.29	CD	0.29	0.29	0.29	N	O
(	(	(	(	(	N	O
0.16	CD	0.16	0.16	0.16	N	O
,	,	,	,	,	N	O
0.51	CD	0.51	0.51	0.51	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
(	(	(	(	(	N	O
GI	NNP	gi	gi	gi	N	O
)	)	)	)	)	N	O
128	CD	128	128	128	N	O
(	(	(	(	(	N	O
0.83	CD	0.83	0.83	0.83	N	O
)	)	)	)	)	N	O
141	CD	141	141	141	N	O
(	(	(	(	(	N	O
0.93	CD	0.93	0.93	0.93	N	O
)	)	)	)	)	N	O
0.89	CD	0.89	0.89	0.89	N	O
(	(	(	(	(	N	O
0.70	CD	0.70	0.70	0.70	N	O
,	,	,	,	,	N	O
1.14	CD	1.14	1.14	1.14	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
0.06	CD	0.06	0.06	0.06	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
0.24	CD	0.24	0.24	0.24	N	O
)	)	)	)	)	N	O
0.27	CD	0.27	0.27	0.27	N	O
(	(	(	(	(	N	O
0.13	CD	0.13	0.13	0.13	N	O
,	,	,	,	,	N	O
0.53	CD	0.53	0.53	0.53	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Intracranial	JJ	intracranial	intracranial	intracrani	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.03	CD	0.03	0.03	0.03	N	O
)	)	)	)	)	N	O
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
0.20	CD	0.20	0.20	0.20	N	O
)	)	)	)	)	N	O
0.13	CD	0.13	0.13	0.13	N	O
(	(	(	(	(	N	O
0.05	CD	0.05	0.05	0.05	N	O
,	,	,	,	,	N	O
0.37	CD	0.37	0.37	0.37	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
0.04	CD	0.04	0.04	0.04	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
0.05	CD	0.05	0.05	0.05	N	O
)	)	)	)	)	N	O
0.84	CD	0.84	0.84	0.84	N	O
(	(	(	(	(	N	O
0.28	CD	0.28	0.28	0.28	N	O
,	,	,	,	,	N	O
2.15	CD	2.15	2.15	2.15	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

In	IN	in	in	in	N	O
ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
for	IN	for	for	for	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
consistent	JJ	consistent	consistent	consist	N	O
across	IN	across	across	across	N	O
most	JJS	most	most	most	N	O
major	JJ	major	major	major	N	O
subgroups	NNS	subgroups	subgroup	subgroup	N	O
including	VBG	including	including	includ	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
weight	NN	weight	weight	weight	Y	O
,	,	,	,	,	N	O
CHADS2score	NNP	chads2score	chads2score	chads2scor	N	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
scale	NN	scale	scale	scale	N	O
from	IN	from	from	from	N	O
0	CD	0	0	0	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
used	VBN	used	used	use	N	O
to	TO	to	to	to	N	O
estimate	VB	estimate	estimate	estim	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
higher	JJR	higher	higher	higher	N	O
scores	NNS	scores	score	score	N	O
predicting	VBG	predicting	predicting	predict	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
prior	RB	prior	prior	prior	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
geographic	JJ	geographic	geographic	geograph	N	O
region	NN	region	region	region	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
aspirin	RB	aspirin	aspirin	aspirin	N	O
use	NN	use	use	use	N	O
at	IN	at	at	at	N	O
randomization	NN	randomization	randomization	random	N	O
(	(	(	(	(	N	O
Figure	NNP	figure	figure	figur	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
bled	VBN	bled	bled	bled	N	B-AdverseReaction
more	JJR	more	more	more	N	O
(	(	(	(	(	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
per	IN	per	per	per	N	O
year	NN	year	year	year	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
did	VBD	did	did	did	N	O
subjects	NNS	subjects	subject	subject	N	O
without	IN	without	without	without	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
per	IN	per	per	per	N	O
year	NN	year	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Figure	NN	figure	figure	figur	N	O

1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Major	JJ	major	major	major	N	B-Severity
Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
Hazard	NNP	hazard	hazard	hazard	N	O
Ratios	NNP	ratios	ratio	ratio	N	O
by	IN	by	by	by	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Characteristics	NNP	characteristics	characteristic	characterist	N	O
-	:	-	-	-	N	O
ARISTOTLE	NN	aristotle	aristotle	aristotl	N	O
Study	NN	study	study	studi	N	O

Note	NN	note	note	note	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
figure	NN	figure	figure	figur	N	O
above	IN	above	above	abov	N	O
presents	NNS	presents	present	present	N	O
effects	NNS	effects	effect	effect	N	O
in	IN	in	in	in	N	O
various	JJ	various	various	variou	N	O
subgroups	NNS	subgroups	subgroup	subgroup	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
baseline	JJ	baseline	baseline	baselin	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
were	VBD	were	were	were	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
specified	VBN	specified	specified	specifi	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
not	RB	not	not	not	N	O
the	DT	the	the	the	N	O
groupings	NNS	groupings	grouping	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
95%	CD	95%	95%	95%	N	O
confidence	NN	confidence	confidence	confid	N	O
limits	NNS	limits	limit	limit	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
do	JJ	do	do	do	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
how	WRB	how	how	how	N	O
many	JJ	many	many	mani	N	O
comparisons	NNS	comparisons	comparison	comparison	N	O
were	VBD	were	were	were	N	O
made	VBN	made	made	made	N	O
,	,	,	,	,	N	O
nor	CC	nor	nor	nor	N	O
do	VBP	do	do	do	N	O
they	PRP	they	they	they	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
particular	JJ	particular	particular	particular	N	O
factor	NN	factor	factor	factor	N	O
after	IN	after	after	after	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Apparent	JJ	apparent	apparent	appar	N	O
homogeneity	NN	homogeneity	homogeneity	homogen	N	O
or	CC	or	or	or	N	O
heterogeneity	NN	heterogeneity	heterogeneity	heterogen	N	O
among	IN	among	among	among	N	O
groups	NNS	groups	group	group	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
over	IN	over	over	over	N	O
-	:	-	-	-	N	O
interpreted	VBN	interpreted	interpreted	interpret	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Bleeding	JJ	bleeding	bleeding	bleed	Y	B-AdverseReaction
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Nonvalvular	NNP	nonvalvular	nonvalvular	nonvalvular	N	O
Atrial	NNP	atrial	atrial	atrial	N	O
Fibrillation	NNP	fibrillation	fibrillation	fibril	Y	O
in	IN	in	in	in	N	O
AVERROES	NNP	averroes	averroes	averro	N	O

ELIQUISN	NN	eliquisn	eliquisn	eliquisn	N	O
2798	CD	2798	2798	2798	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
year	NN	year	year	year	N	O
)	)	)	)	)	N	O
AspirinN	NNP	aspirinn	aspirinn	aspirinn	N	O
2780	CD	2780	2780	2780	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
year	NN	year	year	year	N	O
)	)	)	)	)	N	O
Hazard	NNP	hazard	hazard	hazard	N	O
Ratio	NNP	ratio	ratio	ratio	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
)	)	)	)	)	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
value	NN	value	value	valu	N	O

Events	NNS	events	event	event	N	O

associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
each	DT	each	each	each	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
were	VBD	were	were	were	N	O
counted	VBN	counted	counted	count	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
subject	NN	subject	subject	subject	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
subjects	NNS	subjects	subject	subject	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
contributed	VBN	contributed	contributed	contribut	N	O
events	NNS	events	event	event	N	O
to	TO	to	to	to	N	O
multiple	JJ	multiple	multiple	multipl	N	O
endpoints	NNS	endpoints	endpoint	endpoint	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	O

45	CD	45	45	45	N	O
(	(	(	(	(	N	O
1.41	CD	1.41	1.41	1.41	N	O
)	)	)	)	)	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
0.92	CD	0.92	0.92	0.92	N	O
)	)	)	)	)	N	O
1.54	CD	1.54	1.54	1.54	N	O
(	(	(	(	(	N	O
0.96	CD	0.96	0.96	0.96	N	O
,	,	,	,	,	N	O
2.45	CD	2.45	2.45	2.45	N	O
)	)	)	)	)	N	O
0.07	CD	0.07	0.07	0.07	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.16	CD	0.16	0.16	0.16	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.16	CD	0.16	0.16	0.16	N	O
)	)	)	)	)	N	O
0.99	CD	0.99	0.99	0.99	N	O
(	(	(	(	(	N	O
0.23	CD	0.23	0.23	0.23	N	O
,	,	,	,	,	N	O
4.29	CD	4.29	4.29	4.29	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

Intracranial	JJ	intracranial	intracranial	intracrani	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
0.34	CD	0.34	0.34	0.34	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
0.35	CD	0.35	0.35	0.35	N	O
)	)	)	)	)	N	O
0.99	CD	0.99	0.99	0.99	N	O
(	(	(	(	(	N	O
0.39	CD	0.39	0.39	0.39	N	O
,	,	,	,	,	N	O
2.51	CD	2.51	2.51	2.51	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O

ARISTOTLE	NNP	aristotle	aristotle	aristotl	N	O
Major	NNP	major	major	major	N	B-Severity
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
Forest	NNP	forest	forest	forest	N	O
Plot	NNP	plot	plot	plot	N	O
Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
.	.	.	.	.	N	O

Prophylaxis	NNP	prophylaxis	prophylaxis	prophylaxi	Y	O
of	IN	of	of	of	N	O
Deep	NNP	deep	deep	deep	N	O
Vein	NNP	vein	vein	vein	N	O
Thrombosis	NNP	thrombosis	thrombosis	thrombosi	Y	O
Following	VBG	following	following	follow	N	O
Hip	NNP	hip	hip	hip	N	O
or	CC	or	or	or	N	O
Knee	NNP	knee	knee	knee	N	O
Replacement	NNP	replacement	replacement	replac	N	O
Surgery	NNP	surgery	surgery	surgeri	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
Phase	NNP	phase	phase	phase	N	O
II	NNP	ii	ii	ii	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
Phase	NNP	phase	phase	phase	N	O
III	NNP	iii	iii	iii	N	O
studies	NNS	studies	study	studi	N	O
including	VBG	including	including	includ	N	O
5924	CD	5924	5924	5924	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
undergoing	VBG	undergoing	undergoing	undergo	N	O
major	JJ	major	major	major	N	O
orthopedic	JJ	orthopedic	orthopedic	orthoped	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
lower	JJR	lower	lower	lower	N	O
limbs	NN	limbs	limb	limb	N	O
(	(	(	(	(	N	O
elective	JJ	elective	elective	elect	N	O
hip	NN	hip	hip	hip	N	O
replacement	NN	replacement	replacement	replac	N	O
or	CC	or	or	or	N	O
elective	JJ	elective	elective	elect	N	O
knee	NN	knee	knee	knee	N	O
replacement	NN	replacement	replacement	replac	N	O
)	)	)	)	)	N	O
treated	VBD	treated	treated	treat	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
38	CD	38	38	38	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
total	JJ	total	total	total	N	O
,	,	,	,	,	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
experienced	JJ	experienced	experienced	experienc	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
results	NNS	results	result	result	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
III	NNP	iii	iii	iii	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
study	NN	study	study	studi	N	O
beginning	VBG	beginning	beginning	begin	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Period	NNP	period	period	period	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
Undergoing	NNP	undergoing	undergoing	undergo	N	O
Elective	NNP	elective	elective	elect	N	O
Hip	NNP	hip	hip	hip	N	O
or	CC	or	or	or	N	O
Knee	NNP	knee	knee	knee	N	O
Replacement	NNP	replacement	replacement	replac	N	O
Surgery	NNP	surgery	surgery	surgeri	Y	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
ADVANCE	NNP	advance	advance	advanc	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
Hip	NNP	hip	hip	hip	N	O
Replacement	NNP	replacement	replacement	replac	N	O
Surgery	NNP	surgery	surgery	surgeri	Y	O
ADVANCE	NNP	advance	advance	advanc	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
Knee	NNP	knee	knee	knee	N	O
Replacement	NNP	replacement	replacement	replac	N	O
Surgery	NNP	surgery	surgery	surgeri	Y	O
ADVANCE	NNP	advance	advance	advanc	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
Knee	NNP	knee	knee	knee	N	O
Replacement	NNP	replacement	replacement	replac	N	O
Surgery	NNP	surgery	surgery	surgeri	Y	O

All	DT	all	all	all	N	O

bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
criteria	NNS	criteria	criterion	criteria	N	O
included	VBD	included	included	includ	N	O
surgical	JJ	surgical	surgical	surgic	N	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
.	.	.	.	.	N	O

Includes	NNS	includes	includes	includ	N	O
13	CD	13	13	13	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
before	IN	before	before	befor	N	B-Negation
the	DT	the	the	the	N	I-Negation
first	JJ	first	first	first	N	I-Negation
dose	NN	dose	dose	dose	N	I-Negation
of	IN	of	of	of	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
(	(	(	(	(	N	O
administered	VBN	administered	administered	administ	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
post	RB	post	post	post	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Includes	NNS	includes	includes	includ	N	O
5	CD	5	5	5	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
before	IN	before	before	befor	N	B-Negation
the	DT	the	the	the	N	I-Negation
first	JJ	first	first	first	N	I-Negation
dose	NN	dose	dose	dose	N	I-Negation
of	IN	of	of	of	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
(	(	(	(	(	N	O
administered	VBN	administered	administered	administ	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
post	RB	post	post	post	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

S	NNP	s	s	s	N	O
Intracranial	NNP	intracranial	intracranial	intracrani	N	O
,	,	,	,	,	N	O
intraspinal	JJ	intraspinal	intraspinal	intraspin	N	O
,	,	,	,	,	N	O
intraocular	JJ	intraocular	intraocular	intraocular	N	O
,	,	,	,	,	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
operated	JJ	operated	operated	oper	N	O
joint	NN	joint	joint	joint	N	O
requiring	VBG	requiring	requiring	requir	N	O
re	JJ	re	re	re	N	O
-	:	-	-	-	N	O
operation	NN	operation	operation	oper	N	O
or	CC	or	or	or	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
with	IN	with	with	with	N	O
compartment	JJ	compartment	compartment	compart	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
retroperitoneal	NN	retroperitoneal	retroperitoneal	retroperiton	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
into	IN	into	into	into	N	I-AdverseReaction
an	DT	an	an	an	N	I-AdverseReaction
operated	JJ	operated	operated	oper	N	I-AdverseReaction
joint	NN	joint	joint	joint	N	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
re	JJ	re	re	re	N	O
-	:	-	-	-	N	O
operation	NN	operation	operation	oper	N	O
or	CC	or	or	or	N	O
intervention	NN	intervention	intervention	intervent	N	O
was	VBD	was	wa	wa	N	O
present	JJ	present	present	present	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
this	DT	this	this	thi	N	O
category	NN	category	category	categori	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

Events	NNS	events	event	event	N	O
and	CC	and	and	and	N	O
event	NN	event	event	event	N	O
rates	NNS	rates	rate	rate	N	O
include	VBP	include	include	includ	N	O
one	CD	one	one	one	N	O
enoxaparin	SYM	enoxaparin	enoxaparin	enoxaparin	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
in	IN	in	in	in	N	O
ADVANCE	NNP	advance	advance	advanc	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
who	WP	who	who	who	N	O
also	RB	also	also	also	N	O
had	VBD	had	had	had	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
.	.	.	.	.	N	O

CRNM	NNP	crnm	crnm	crnm	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
nonmajor	NN	nonmajor	nonmajor	nonmajor	N	O
.	.	.	.	.	N	O

ELIQUIS2	NN	eliquis2	eliquis2	eliquis2	N	O

.	.	.	.	.	N	O
5	CD	5	5	5	N	O
mg	JJ	mg	mg	mg	N	O
po	NN	po	po	po	N	O
bid35	SYM	bid35	bid35	bid35	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
Enoxaparin	NNP	enoxaparin	enoxaparin	enoxaparin	N	O
40	CD	40	40	40	N	O
mg	NN	mg	mg	mg	N	O
sc	NN	sc	sc	sc	N	O
qd	VBD	qd	qd	qd	N	O
35	CD	35	35	35	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
po	NN	po	po	po	N	O
bid	NN	bid	bid	bid	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O
Enoxaparin	NNP	enoxaparin	enoxaparin	enoxaparin	N	O
40	CD	40	40	40	N	O
mg	NN	mg	mg	mg	N	O
sc	NN	sc	sc	sc	N	O
qd	VBD	qd	qd	qd	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
po	NN	po	po	po	N	O
bid	NN	bid	bid	bid	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O
Enoxaparin	NNP	enoxaparin	enoxaparin	enoxaparin	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
sc	NN	sc	sc	sc	N	O
q12h	VBD	q12h	q12h	q12h	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O

First	RB	first	first	first	N	O
dose	RB	dose	dose	dose	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
post	NN	post	post	post	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
First	NNP	first	first	first	N	O
dose	VBZ	dose	dose	dose	N	O
9	CD	9	9	9	N	O
to	TO	to	to	to	N	O
15	CD	15	15	15	N	O
hours	NNS	hours	hour	hour	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
surgery	VB	surgery	surgery	surgeri	Y	O
First	NNP	first	first	first	N	O
dose	VB	dose	dose	dose	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
post	NN	post	post	post	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
First	NNP	first	first	first	N	O
dose	VBZ	dose	dose	dose	N	O
9	CD	9	9	9	N	O
to	TO	to	to	to	N	O
15	CD	15	15	15	N	O
hours	NNS	hours	hour	hour	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
surgery	VB	surgery	surgery	surgeri	Y	O
First	NNP	first	first	first	N	O
dose	VB	dose	dose	dose	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
post	NN	post	post	post	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
First	NNP	first	first	first	N	O
dose	VBZ	dose	dose	dose	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
post	NN	post	post	post	N	O
surgery	NN	surgery	surgery	surgeri	Y	O

All	DT	all	all	all	N	O
treated	VBD	treated	treated	treat	N	O
N	NNP	n	n	n	N	O
2673	CD	2673	2673	2673	N	O
N	NNP	n	n	n	N	O
2659	CD	2659	2659	2659	N	O
N	NNP	n	n	n	N	O
1501	CD	1501	1501	1501	N	O
N	NNP	n	n	n	N	O
1508	CD	1508	1508	1508	N	O
N	NNP	n	n	n	N	O
1596	CD	1596	1596	1596	N	O
N	NNP	n	n	n	N	O
1588	CD	1588	1588	1588	N	O

Major	NNP	major	major	major	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
surgical	JJ	surgical	surgical	surgic	N	O
site	NN	site	site	site	N	O
)	)	)	)	)	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
0.82%	CD	0.82%	0.82%	0.82%	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
0.68%	CD	0.68%	0.68%	0.68%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
0.60%	CD	0.60%	0.60%	0.60%	N	O
)	)	)	)	)	N	O
?	.	?	?	?	N	O

14	CD	14	14	14	N	O
(	(	(	(	(	N	O
0.93%	CD	0.93%	0.93%	0.93%	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
0.69%	CD	0.69%	0.69%	0.69%	N	O
)	)	)	)	)	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
1.39%	CD	1.39%	1.39%	1.39%	N	O
)	)	)	)	)	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.06%	CD	0.06%	0.06%	0.06%	N	O
)	)	)	)	)	N	O

Hgb	NNP	hgb	hgb	hgb	N	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
2	CD	2	2	2	N	B-Severity
g	NN	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
0.49%	CD	0.49%	0.49%	0.49%	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
0.38%	CD	0.38%	0.38%	0.38%	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
0.53%	CD	0.53%	0.53%	0.53%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
0.60%	CD	0.60%	0.60%	0.60%	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
0.63%	CD	0.63%	0.63%	0.63%	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
1.01%	CD	1.01%	1.01%	1.01%	N	O
)	)	)	)	)	N	O

Transfusion	NN	transfusion	transfusion	transfus	Y	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
units	NNS	units	unit	unit	N	O
RBC	NNP	rbc	rbc	rbc	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
0.60%	CD	0.60%	0.60%	0.60%	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
0.53%	CD	0.53%	0.53%	0.53%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.33%	CD	0.33%	0.33%	0.33%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
0.60%	CD	0.60%	0.60%	0.60%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
0.56%	CD	0.56%	0.56%	0.56%	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
1.13%	CD	1.13%	1.13%	1.13%	N	O
)	)	)	)	)	N	O

Bleed	VBN	bleed	bleed	bleed	N	B-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
critical	JJ	critical	critical	critic	N	I-AdverseReaction
siteS	NN	sites	site	site	N	I-AdverseReaction
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.04%	CD	0.04%	0.04%	0.04%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.04%	CD	0.04%	0.04%	0.04%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.07%	CD	0.07%	0.07%	0.07%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.13%	CD	0.13%	0.13%	0.13%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.06%	CD	0.06%	0.06%	0.06%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.25%	CD	0.25%	0.25%	0.25%	N	O
)	)	)	)	)	N	O

Major	JJ	major	major	major	N	O
CRNM	NNP	crnm	crnm	crnm	N	O
129	CD	129	129	129	N	O
(	(	(	(	(	N	O
4.83%	CD	4.83%	4.83%	4.83%	N	O
)	)	)	)	)	N	O
134	CD	134	134	134	N	O
(	(	(	(	(	N	O
5.04%	CD	5.04%	5.04%	5.04%	N	O
)	)	)	)	)	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
3.53%	CD	3.53%	3.53%	3.53%	N	O
)	)	)	)	)	N	O
72	CD	72	72	72	N	O
(	(	(	(	(	N	O
4.77%	CD	4.77%	4.77%	4.77%	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
2.88%	CD	2.88%	2.88%	2.88%	N	O
)	)	)	)	)	N	O
68	CD	68	68	68	N	O
(	(	(	(	(	N	O
4.28%	CD	4.28%	4.28%	4.28%	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
313	CD	313	313	313	N	O
(	(	(	(	(	N	O
11.71%	CD	11.71%	11.71%	11.71%	N	O
)	)	)	)	)	N	O
334	CD	334	334	334	N	O
(	(	(	(	(	N	O
12.56%	CD	12.56%	12.56%	12.56%	N	O
)	)	)	)	)	N	O
104	CD	104	104	104	N	O
(	(	(	(	(	N	O
6.93%	CD	6.93%	6.93%	6.93%	N	O
)	)	)	)	)	N	O
126	CD	126	126	126	N	O
(	(	(	(	(	N	O
8.36%	CD	8.36%	8.36%	8.36%	N	O
)	)	)	)	)	N	O
85	CD	85	85	85	N	O
(	(	(	(	(	N	O
5.33%	CD	5.33%	5.33%	5.33%	N	O
)	)	)	)	)	N	O
108	CD	108	108	108	N	O
(	(	(	(	(	N	O
6.80%	CD	6.80%	6.80%	6.80%	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
undergoing	VBG	undergoing	undergoing	undergo	N	O
hip	NN	hip	hip	hip	N	O
or	CC	or	or	or	N	O
knee	VB	knee	knee	knee	N	O
replacement	NN	replacement	replacement	replac	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
Phase	NNP	phase	phase	phase	N	O
II	NNP	ii	ii	ii	N	O
study	NN	study	study	studi	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
Phase	NNP	phase	phase	phase	N	O
III	NNP	iii	iii	iii	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Either	NNP	either	either	either	N	O
Group	NNP	group	group	group	N	O
Undergoing	NNP	undergoing	undergoing	undergo	N	O
Hip	NNP	hip	hip	hip	N	O
or	CC	or	or	or	N	O
Knee	NNP	knee	knee	knee	N	O
Replacement	NNP	replacement	replacement	replac	N	O
Surgery	NNP	surgery	surgery	surgeri	Y	O

ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
,	,	,	,	,	N	O
n	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
po	NN	po	po	po	N	O
bidN	NN	bidn	bidn	bidn	N	O
5924	CD	5924	5924	5924	N	O
Enoxaparin	NNP	enoxaparin	enoxaparin	enoxaparin	N	O
,	,	,	,	,	N	O
n	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
40	CD	40	40	40	N	O
mg	NN	mg	mg	mg	N	O
sc	NN	sc	sc	sc	N	O
qd	NN	qd	qd	qd	N	O
or30	NN	or30	or30	or30	N	O
mg	NN	mg	mg	mg	N	O
sc	NN	sc	sc	sc	N	O
q12hN	NN	q12hn	q12hn	q12hn	N	O
5904	CD	5904	5904	5904	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction

153	CD	153	153	153	N	O
(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
159	CD	159	159	159	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
postoperative	NN	postoperative	postoperative	postop	N	B-AdverseReaction
and	CC	and	and	and	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
respective	JJ	respective	respective	respect	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
parameters	NNS	parameters	parameter	paramet	N	O
)	)	)	)	)	N	O
153	CD	153	153	153	N	O
(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
178	CD	178	178	178	N	O
(	(	(	(	(	N	O
3.0	CD	3.0	3.0	3.0	N	O
)	)	)	)	)	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
83	CD	83	83	83	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
1.9	CD	1.9	1.9	1.9	N	O
)	)	)	)	)	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
and	CC	and	and	and	N	O
urethral	JJ	urethral	urethral	urethr	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
67	CD	67	67	67	N	O
(	(	(	(	(	N	O
1.1	CD	1.1	1.1	1.1	N	O
)	)	)	)	)	N	O
81	CD	81	81	81	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O

Postprocedural	JJ	postprocedural	postprocedural	postprocedur	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
postprocedural	JJ	postprocedural	postprocedural	postprocedur	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
wound	NN	wound	wound	wound	Y	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
vessel	JJ	vessel	vessel	vessel	N	B-AdverseReaction
puncture	NN	puncture	puncture	punctur	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
and	CC	and	and	and	N	O
catheter	NN	catheter	catheter	cathet	N	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
54	CD	54	54	54	N	O
(	(	(	(	(	N	O
0.9	CD	0.9	0.9	0.9	N	O
)	)	)	)	)	N	O
60	CD	60	60	60	N	O
(	(	(	(	(	N	O
1.0	CD	1.0	1.0	1.0	N	O
)	)	)	)	)	N	O

Transaminases	NNS	transaminases	transaminase	transaminas	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
and	CC	and	and	and	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
abnormal	NN	abnormal	abnormal	abnorm	N	I-AdverseReaction
)	)	)	)	)	N	O
50	CD	50	50	50	N	O
(	(	(	(	(	N	O
0.8	CD	0.8	0.8	0.8	N	O
)	)	)	)	)	N	O
71	CD	71	71	71	N	O
(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
)	)	)	)	)	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
47	CD	47	47	47	N	O
(	(	(	(	(	N	O
0.8	CD	0.8	0.8	0.8	N	O
)	)	)	)	)	N	O
69	CD	69	69	69	N	O
(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
)	)	)	)	)	N	O

Gamma	NNP	gamma	gamma	gamma	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
glutamyltransferase	NN	glutamyltransferase	glutamyltransferase	glutamyltransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
65	CD	65	65	65	N	O
(	(	(	(	(	N	O
1.1	CD	1.1	1.1	1.1	N	O
)	)	)	)	)	N	O

Less	NNP	less	le	less	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
apixaban	JJ	apixaban	apixaban	apixaban	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
undergoing	VBG	undergoing	undergoing	undergo	N	O
hip	NN	hip	hip	hip	N	O
or	CC	or	or	or	N	O
knee	VB	knee	knee	knee	N	O
replacement	NN	replacement	replacement	replac	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
:	:	:	:	:	N	O

Blood	NN	blood	blood	blood	N	O

and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
platelet	NN	platelet	platelet	platelet	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreases	NNS	decreases	decrease	decreas	N	I-AdverseReaction
)	)	)	)	)	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
procedural	JJ	procedural	procedural	procedur	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
hematemesis	NN	hematemesis	hematemesis	hematemesi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
melena	NN	melena	melena	melena	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hematochezia	NN	hematochezia	hematochezia	hematochezia	Y	B-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
liver	NN	liver	liver	liver	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormal	NN	abnormal	abnormal	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
respective	JJ	respective	respective	respect	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
parameters	NNS	parameters	parameter	paramet	N	O
)	)	)	)	)	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O
:	:	:	:	:	N	O
wound	NN	wound	wound	wound	Y	B-AdverseReaction
secretion	NN	secretion	secretion	secret	N	I-AdverseReaction
,	,	,	,	,	N	O
incision	NN	incision	incision	incis	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
incision	NN	incision	incision	incis	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
operative	JJ	operative	operative	oper	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction

Less	NNP	less	le	less	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
apixaban	JJ	apixaban	apixaban	apixaban	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
undergoing	VBG	undergoing	undergoing	undergo	N	O
hip	NN	hip	hip	hip	N	O
or	CC	or	or	or	N	O
knee	VB	knee	knee	knee	N	O
replacement	NN	replacement	replacement	replac	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
:	:	:	:	:	N	O

Gingival	NNP	gingival	gingival	gingiv	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
ocular	JJ	ocular	ocular	ocular	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
conjunctival	JJ	conjunctival	conjunctival	conjunctiv	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rectal	JJ	rectal	rectal	rectal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
DVT	NNP	dvt	dvt	dvt	Y	O
and	CC	and	and	and	N	O
PE	NNP	pe	pe	pe	N	O
and	CC	and	and	and	N	O
Reduction	NNP	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Recurrence	NNP	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
DVT	NNP	dvt	dvt	dvt	Y	O
or	CC	or	or	or	N	O
PE	NNP	pe	pe	pe	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
and	CC	and	and	and	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NNP	ext	ext	ext	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
2676	CD	2676	2676	2676	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
3359	CD	3359	3359	3359	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
840	CD	840	840	840	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
gingival	JJ	gingival	gingival	gingiv	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
rectal	JJ	rectal	rectal	rectal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
menorrhagia	NN	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
.	.	.	.	.	N	O

AMPLIFY	NNP	amplify	amplify	amplifi	N	O
Study	NNP	study	study	studi	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
was	VBD	was	wa	wa	N	O
154	CD	154	154	154	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
enoxaparin	VB	enoxaparin	enoxaparin	enoxaparin	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
was	VBD	was	wa	wa	N	O
152	CD	152	152	152	N	O
days	NNS	days	day	day	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
417	CD	417	417	417	N	O
(	(	(	(	(	N	O
15.6%	CD	15.6%	15.6%	15.6%	N	O
)	)	)	)	)	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
661	CD	661	661	661	N	O
(	(	(	(	(	N	O
24.6%	CD	24.6%	24.6%	24.6%	N	O
)	)	)	)	)	N	O
enoxaparin	NN	enoxaparin	enoxaparin	enoxaparin	N	O
warfarin	SYM	warfarin	warfarin	warfarin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
rate	NN	rate	rate	rate	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
in	IN	in	in	in	N	O
enoxaparin	NN	enoxaparin	enoxaparin	enoxaparin	N	O
warfarin	SYM	warfarin	warfarin	warfarin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
was	VBD	was	wa	wa	N	O
statistically	RB	statistically	statistically	statist	N	O
superior	JJ	superior	superior	superior	N	O
to	TO	to	to	to	N	O
enoxaparin	VB	enoxaparin	enoxaparin	enoxaparin	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
primary	JJ	primary	primary	primari	N	O
safety	NN	safety	safety	safeti	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
of	IN	of	of	of	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
(	(	(	(	(	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
0.31	CD	0.31	0.31	0.31	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
[	NNP	[	[	[	N	O
0.17	CD	0.17	0.17	0.17	N	O
,	,	,	,	,	N	O
0.55	CD	0.55	0.55	0.55	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
value	NN	value	value	valu	N	O
0.0001	CD	0.0001	0.0001	0.0001	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
results	NNS	results	result	result	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
study	NN	study	study	studi	N	O
are	VBP	are	are	are	N	O
summarized	VBN	summarized	summarized	summar	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
Results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
Study	NNP	study	study	studi	N	O

ELIQUISN	NN	eliquisn	eliquisn	eliquisn	N	O
2676	CD	2676	2676	2676	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Enoxaparin	NNP	enoxaparin	enoxaparin	enoxaparin	N	O
WarfarinN	NNP	warfarinn	warfarinn	warfarinn	N	O
2689	CD	2689	2689	2689	N	O
n	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Relative	NNP	relative	relative	rel	N	O
Risk	NNP	risk	risk	risk	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
)	)	)	)	)	N	O

CRNM	NN	crnm	crnm	crnm	N	B-AdverseReaction

clinically	RB	clinically	clinically	clinic	N	B-AdverseReaction
relevant	JJ	relevant	relevant	relev	N	I-AdverseReaction
nonmajor	JJ	nonmajor	nonmajor	nonmajor	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
.	.	.	.	.	N	O
Events	NNS	events	event	event	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
each	DT	each	each	each	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
were	VBD	were	were	were	N	O
counted	VBN	counted	counted	count	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
subject	NN	subject	subject	subject	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
subjects	NNS	subjects	subject	subject	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
contributed	VBN	contributed	contributed	contribut	N	O
events	NNS	events	event	event	N	O
to	TO	to	to	to	N	O
multiple	JJ	multiple	multiple	multipl	N	O
endpoints	NNS	endpoints	endpoint	endpoint	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	O

15	CD	15	15	15	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
49	CD	49	49	49	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
0.31	CD	0.31	0.31	0.31	N	O
(	(	(	(	(	N	O
0.17	CD	0.17	0.17	0.17	N	O
,	,	,	,	,	N	O
0.55	CD	0.55	0.55	0.55	N	O
)	)	)	)	)	N	O
p	NN	p	p	p	Y	O
0.0001	CD	0.0001	0.0001	0.0001	N	O

CRNM	NNP	crnm	crnm	crnm	N	B-AdverseReaction
103	CD	103	103	103	N	O
(	(	(	(	(	N	O
3.9	CD	3.9	3.9	3.9	N	O
)	)	)	)	)	N	O
215	CD	215	215	215	N	O
(	(	(	(	(	N	O
8.0	CD	8.0	8.0	8.0	N	O
)	)	)	)	)	N	O

Major	JJ	major	major	major	N	O
CRNM	NNP	crnm	crnm	crnm	N	B-AdverseReaction
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
4.3	CD	4.3	4.3	4.3	N	O
)	)	)	)	)	N	O
261	CD	261	261	261	N	O
(	(	(	(	(	N	O
9.7	CD	9.7	9.7	9.7	N	O
)	)	)	)	)	N	O

Minor	JJ	minor	minor	minor	N	O
313	CD	313	313	313	N	O
(	(	(	(	(	N	O
11.7	CD	11.7	11.7	11.7	N	O
)	)	)	)	)	N	O
505	CD	505	505	505	N	O
(	(	(	(	(	N	O
18.8	CD	18.8	18.8	18.8	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
402	CD	402	402	402	N	O
(	(	(	(	(	N	O
15.0	CD	15.0	15.0	15.0	N	O
)	)	)	)	)	N	O
676	CD	676	676	676	N	O
(	(	(	(	(	N	O
25.1	CD	25.1	25.1	25.1	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
study	NN	study	study	studi	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
DVT	NNP	dvt	dvt	dvt	Y	O
and	CC	and	and	and	N	O
PE	NNP	pe	pe	pe	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
Study	NNP	study	study	studi	N	O

ELIQUISN	NN	eliquisn	eliquisn	eliquisn	N	O
2676	CD	2676	2676	2676	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Enoxaparin	NNP	enoxaparin	enoxaparin	enoxaparin	N	O
WarfarinN	NNP	warfarinn	warfarinn	warfarinn	N	O
2689	CD	2689	2689	2689	N	O
n	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction

77	CD	77	77	77	N	O
(	(	(	(	(	N	O
2.9	CD	2.9	2.9	2.9	N	O
)	)	)	)	)	N	O
146	CD	146	146	146	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
49	CD	49	49	49	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
97	CD	97	97	97	N	O
(	(	(	(	(	N	O
3.6	CD	3.6	3.6	3.6	N	O
)	)	)	)	)	N	O

Hematuria	$	hematuria	hematuria	hematuria	Y	B-AdverseReaction
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
1.7	CD	1.7	1.7	1.7	N	O
)	)	)	)	)	N	O
102	CD	102	102	102	N	O
(	(	(	(	(	N	O
3.8	CD	3.8	3.8	3.8	N	O
)	)	)	)	)	N	O

Menorrhagia	NNP	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
1.1	CD	1.1	1.1	1.1	N	O
)	)	)	)	)	N	O

Hematoma	$	hematoma	hematoma	hematoma	Y	B-AdverseReaction
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
1.3	CD	1.3	1.3	1.3	N	O
)	)	)	)	)	N	O
76	CD	76	76	76	N	O
(	(	(	(	(	N	O
2.8	CD	2.8	2.8	2.8	N	O
)	)	)	)	)	N	O

Hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
32	CD	32	32	32	N	O
(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
)	)	)	)	)	N	O
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
)	)	)	)	)	N	O

Rectal	JJ	rectal	rectal	rectal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
1.0	CD	1.0	1.0	1.0	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
1.5	CD	1.5	1.5	1.5	N	O
)	)	)	)	)	N	O

Gingival	NNP	gingival	gingival	gingiv	N	B-AdverseReaction
bleeding	VBG	bleeding	bleeding	bleed	Y	I-AdverseReaction
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
1.0	CD	1.0	1.0	1.0	N	O
)	)	)	)	)	N	O
50	CD	50	50	50	N	O
(	(	(	(	(	N	O
1.9	CD	1.9	1.9	1.9	N	O
)	)	)	)	)	N	O

AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
Study	NN	study	study	studi	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
330	CD	330	330	330	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
312	CD	312	312	312	N	O
days	NNS	days	day	day	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
219	CD	219	219	219	N	O
(	(	(	(	(	N	O
13.3%	CD	13.3%	13.3%	13.3%	N	O
)	)	)	)	)	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
72	CD	72	72	72	N	O
(	(	(	(	(	N	O
8.7%	CD	8.7%	8.7%	8.7%	N	O
)	)	)	)	)	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
rate	NN	rate	rate	rate	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
results	NNS	results	result	result	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
study	NN	study	study	studi	N	O
are	VBP	are	are	are	N	O
summarized	VBN	summarized	summarized	summar	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
:	:	:	:	:	N	O
Bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
Results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
Study	NN	study	study	studi	N	O

ELIQUIS	RB	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
bidN	VBD	bidn	bidn	bidn	N	O
840	CD	840	840	840	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
bidN	NN	bidn	bidn	bidn	N	O
811	CD	811	811	811	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
PlaceboN	VBZ	placebon	placebon	placebon	N	O
826	CD	826	826	826	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

CRNM	NN	crnm	crnm	crnm	N	B-AdverseReaction

clinically	RB	clinically	clinically	clinic	N	B-AdverseReaction
relevant	JJ	relevant	relevant	relev	N	I-AdverseReaction
nonmajor	JJ	nonmajor	nonmajor	nonmajor	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
.	.	.	.	.	N	O
Events	NNS	events	event	event	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
each	DT	each	each	each	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
were	VBD	were	were	were	N	O
counted	VBN	counted	counted	count	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
subject	NN	subject	subject	subject	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
subjects	NNS	subjects	subject	subject	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
contributed	VBN	contributed	contributed	contribut	N	O
events	NNS	events	event	event	N	O
to	TO	to	to	to	N	O
multiple	JJ	multiple	multiple	multipl	N	O
endpoints	NNS	endpoints	endpoint	endpoint	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	O

2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.2	CD	0.2	0.2	0.2	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.1	CD	0.1	0.1	0.1	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.5	CD	0.5	0.5	0.5	N	O
)	)	)	)	)	N	O

CRNM	NNP	crnm	crnm	crnm	N	B-AdverseReaction
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
3.0	CD	3.0	3.0	3.0	N	O
)	)	)	)	)	N	O
34	CD	34	34	34	N	O
(	(	(	(	(	N	O
4.2	CD	4.2	4.2	4.2	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Major	JJ	major	major	major	N	O
CRNM	NNP	crnm	crnm	crnm	N	B-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
3.2	CD	3.2	3.2	3.2	N	O
)	)	)	)	)	N	O
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
4.3	CD	4.3	4.3	4.3	N	O
)	)	)	)	)	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O

Minor	JJ	minor	minor	minor	N	O
75	CD	75	75	75	N	O
(	(	(	(	(	N	O
8.9	CD	8.9	8.9	8.9	N	O
)	)	)	)	)	N	O
98	CD	98	98	98	N	O
(	(	(	(	(	N	O
12.1	CD	12.1	12.1	12.1	N	O
)	)	)	)	)	N	O
58	CD	58	58	58	N	O
(	(	(	(	(	N	O
7.0	CD	7.0	7.0	7.0	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
94	CD	94	94	94	N	O
(	(	(	(	(	N	O
11.2	CD	11.2	11.2	11.2	N	O
)	)	)	)	)	N	O
121	CD	121	121	121	N	O
(	(	(	(	(	N	O
14.9	CD	14.9	14.9	14.9	N	O
)	)	)	)	)	N	O
74	CD	74	74	74	N	O
(	(	(	(	(	N	O
9.0	CD	9.0	9.0	9.0	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
study	NN	study	study	studi	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

8	CD	8	8	8	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Undergoing	VBG	undergoing	undergoing	undergo	N	O
Extended	NNP	extended	extended	extend	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
DVT	NNP	dvt	dvt	dvt	Y	O
and	CC	and	and	and	N	O
PE	NNP	pe	pe	pe	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NN	ext	ext	ext	N	O
Study	NN	study	study	studi	N	O

ELIQUIS	RB	eliquis	eliquis	eliqui	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
bidN	VBD	bidn	bidn	bidn	N	O
840	CD	840	840	840	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
bidN	NN	bidn	bidn	bidn	N	O
811	CD	811	811	811	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
PlaceboN	VBZ	placebon	placebon	placebon	N	O
826	CD	826	826	826	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction

13	CD	13	13	13	N	O
(	(	(	(	(	N	O
1.5	CD	1.5	1.5	1.5	N	O
)	)	)	)	)	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
3.6	CD	3.6	3.6	3.6	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1.1	CD	1.1	1.1	1.1	N	O
)	)	)	)	)	N	O

Hematuria	$	hematuria	hematuria	hematuria	Y	B-AdverseReaction
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1.1	CD	1.1	1.1	1.1	N	O
)	)	)	)	)	N	O

Hematoma	$	hematoma	hematoma	hematoma	Y	B-AdverseReaction
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
1.5	CD	1.5	1.5	1.5	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
2.0	CD	2.0	2.0	2.0	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
)	)	)	)	)	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O

Gingival	NNP	gingival	gingival	gingiv	N	B-AdverseReaction
bleeding	VBG	bleeding	bleeding	bleed	Y	I-AdverseReaction
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1.1	CD	1.1	1.1	1.1	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Less	NNP	less	le	less	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
or	CC	or	or	or	N	O
AMPLIFY	NNP	amplify	amplify	amplifi	N	O
-	:	-	-	-	N	O
EXT	NNP	ext	ext	ext	N	O
studies	NNS	studies	study	studi	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
:	:	:	:	:	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hemorrhagic	NN	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hematochezia	NN	hematochezia	hematochezia	hematochezia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hemorrhoidal	JJ	hemorrhoidal	hemorrhoidal	hemorrhoid	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematemesis	NN	hematemesis	hematemesis	hematemesi	Y	B-AdverseReaction
,	,	,	,	,	N	O
melena	NN	melena	melena	melena	Y	B-AdverseReaction
,	,	,	,	,	N	O
anal	JJ	anal	anal	anal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O
:	:	:	:	:	N	O
wound	NN	wound	wound	wound	Y	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
postprocedural	JJ	postprocedural	postprocedural	postprocedur	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
traumatic	JJ	traumatic	traumatic	traumat	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
periorbital	JJ	periorbital	periorbital	periorbit	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
system	NN	system	system	system	N	O
and	CC	and	and	and	N	O
breast	NN	breast	breast	breast	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
metrorrhagia	NN	metrorrhagia	metrorrhagia	metrorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
menometrorrhagia	NN	menometrorrhagia	menometrorrhagia	menometrorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
ecchymosis	NN	ecchymosis	ecchymosis	ecchymosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
petechiae	NN	petechiae	petechia	petechia	Y	B-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
conjunctival	NN	conjunctival	conjunctival	conjunctiv	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
urine	JJ	urine	urine	urin	N	I-AdverseReaction
present	NN	present	present	present	N	I-AdverseReaction
,	,	,	,	,	N	O
occult	NN	occult	occult	occult	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
positive	JJ	positive	positive	posit	N	I-AdverseReaction
,	,	,	,	,	N	O
occult	JJ	occult	occult	occult	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
,	,	,	,	,	N	O
red	JJ	red	red	red	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cells	NNS	cells	cell	cell	N	I-AdverseReaction
urine	JJ	urine	urine	urin	N	I-AdverseReaction
positive	JJ	positive	positive	posit	N	I-AdverseReaction

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
-	:	-	-	-	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
vessel	JJ	vessel	vessel	vessel	N	B-AdverseReaction
puncture	NN	puncture	puncture	punctur	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	B-AdverseReaction
EPIDURAL	NNP	epidural	epidural	epidur	N	B-AdverseReaction
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	B-AdverseReaction
EPIDURAL	NNP	epidural	epidural	epidur	N	B-AdverseReaction
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
A	NNP	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Premature	NNP	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
,	,	,	,	,	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anticoagulation	NN	anticoagulation	anticoagulation	anticoagul	N	O
with	IN	with	with	with	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
coverage	NN	coverage	coverage	coverag	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
\n\n\n\n	NN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	O
EPIDURAL	NNP	epidural	epidural	epidur	N	O
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Epidural	NNP	epidural	epidural	epidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematomas	NN	hematomas	hematoma	hematoma	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
receiving	VBG	receiving	receiving	receiv	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
undergoing	JJ	undergoing	undergoing	undergo	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
hematomas	NN	hematomas	hematoma	hematoma	N	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
term	NN	term	term	term	N	I-AdverseReaction
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
paralysis	NN	paralysis	paralysis	paralysi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
these	DT	these	these	these	N	O
risks	NNS	risks	risk	risk	N	O
when	WRB	when	when	when	N	O
scheduling	VBG	scheduling	scheduling	schedul	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
spinal	JJ	spinal	spinal	spinal	N	O
procedures	NNS	procedures	procedure	procedur	N	O
.	.	.	.	.	N	O

Factors	NNS	factors	factor	factor	N	O
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
epidural	JJ	epidural	epidural	epidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematomas	NN	hematomas	hematoma	hematoma	N	I-AdverseReaction
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
\n\n\n\n	VB	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
?	.	?	?	?	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
indwelling	VBG	indwelling	indwelling	indwel	N	O
epidural	JJ	epidural	epidural	epidur	N	O
catheters	NNS	catheters	catheter	cathet	N	O
\n	POS	\n	\n	\n	N	O
?	.	?	?	?	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	IN	that	that	that	N	O
affect	JJ	affect	affect	affect	N	O
hemostasis	NN	hemostasis	hemostasis	hemostasi	Y	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
nonsteroidal	JJ	nonsteroidal	nonsteroidal	nonsteroid	N	O
anti	IN	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
(	(	(	(	(	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
platelet	JJ	platelet	platelet	platelet	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
anticoagulants	NNS	anticoagulants	anticoagulant	anticoagul	N	O
\n	VB	\n	\n	\n	N	O
?	.	?	?	?	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
traumatic	JJ	traumatic	traumatic	traumat	N	O
or	CC	or	or	or	N	O
repeated	JJ	repeated	repeated	repeat	N	O
epidural	JJ	epidural	epidural	epidur	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
punctures	NNS	punctures	puncture	punctur	N	O
\n	VBN	\n	\n	\n	N	O
?	.	?	?	?	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
spinal	JJ	spinal	spinal	spinal	N	O
deformity	NN	deformity	deformity	deform	Y	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
\n	NN	\n	\n	\n	N	O
?	.	?	?	?	N	O
optimal	JJ	optimal	optimal	optim	N	O
timing	NN	timing	timing	time	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
and	CC	and	and	and	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
procedures	NNS	procedures	procedure	procedur	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
\n	JJ	\n	\n	\n	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NNP	)]	)]	)]	N	O
\n	NNP	\n	\n	\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
frequently	RB	frequently	frequently	frequent	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
compromise	NN	compromise	compromise	compromis	N	O
is	VBZ	is	is	is	N	O
noted	VBN	noted	noted	note	N	O
,	,	,	,	,	N	O
urgent	JJ	urgent	urgent	urgent	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
necessary	JJ	necessary	necessary	necessari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
before	IN	before	before	befor	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
intervention	NN	intervention	intervention	intervent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
anticoagulated	VBD	anticoagulated	anticoagulated	anticoagul	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
anticoagulated	VBN	anticoagulated	anticoagulated	anticoagul	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	B-AdverseReaction
EPIDURAL	NNP	epidural	epidural	epidur	N	B-AdverseReaction
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
:	:	:	:	:	N	O
Premature	JJ	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
,	,	,	,	,	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
this	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
coverage	NN	coverage	coverage	coverag	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
if	IN	if	if	if	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
\n\n\n\n	NN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	O
EPIDURAL	NNP	epidural	epidural	epidur	N	O
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	O
:	:	:	:	:	N	O
Epidural	JJ	epidural	epidural	epidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematomas	NN	hematomas	hematoma	hematoma	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
receiving	VBG	receiving	receiving	receiv	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
undergoing	JJ	undergoing	undergoing	undergo	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
hematomas	NN	hematomas	hematoma	hematoma	N	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
term	NN	term	term	term	N	I-AdverseReaction
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
paralysis	NN	paralysis	paralysis	paralysi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
these	DT	these	these	these	N	O
risks	NNS	risks	risk	risk	N	O
when	WRB	when	when	when	N	O
scheduling	VBG	scheduling	scheduling	schedul	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
spinal	JJ	spinal	spinal	spinal	N	O
procedures	NNS	procedures	procedure	procedur	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
?	.	?	?	?	N	O

ELIQUIS	NNS	eliquis	eliquis	eliqui	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
,	,	,	,	,	N	O
potentially	RB	potentially	potentially	potenti	N	B-Factor
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

Promptly	RB	promptly	promptly	promptli	N	O
evaluate	JJ	evaluate	evaluate	evalu	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

?	.	?	?	?	N	O

Prosthetic	JJ	prosthetic	prosthetic	prosthet	N	O
heart	NN	heart	heart	heart	N	O
valves	NNS	valves	valve	valv	N	O
:	:	:	:	:	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
use	NN	use	use	use	N	O
not	RB	not	not	not	N	O
recommended	VBD	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Increased	VBN	increased	increased	increas	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
Events	NNS	events	event	event	N	O
after	IN	after	after	after	N	O
Premature	NNP	premature	premature	prematur	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O

Premature	JJ	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
adequate	JJ	adequate	adequate	adequ	N	O
alternative	JJ	alternative	alternative	altern	N	O
anticoagulation	NN	anticoagulation	anticoagulation	anticoagul	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
transition	NN	transition	transition	transit	N	O
from	IN	from	from	from	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
to	TO	to	to	to	N	O
warfarin	VB	warfarin	warfarin	warfarin	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
coverage	NN	coverage	coverage	coverag	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)	)	)	)	)	N	O
andClinical	JJ	andclinical	andclinical	andclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Bleeding	NN	bleeding	bleeding	bleed	Y	O

ELIQUIS	NN	eliquis	eliquis	eliqui	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
and	CC	and	and	and	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
,	,	,	,	,	N	O
potentially	RB	potentially	potentially	potenti	N	B-Factor
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
andAdverse	NN	andadverse	andadverse	andadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
affecting	VBG	affecting	affecting	affect	N	O
hemostasis	NN	hemostasis	hemostasis	hemostasi	Y	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
include	VBP	include	include	includ	N	O
aspirin	NNS	aspirin	aspirin	aspirin	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
antiplatelet	NN	antiplatelet	antiplatelet	antiplatelet	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
anticoagulants	NNS	anticoagulants	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
heparin	NN	heparin	heparin	heparin	N	O
,	,	,	,	,	N	O
thrombolytic	JJ	thrombolytic	thrombolytic	thrombolyt	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
selective	JJ	selective	selective	select	N	O
serotonin	NN	serotonin	serotonin	serotonin	N	O
reuptake	NN	reuptake	reuptake	reuptak	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
serotonin	JJ	serotonin	serotonin	serotonin	N	O
norepinephrine	JJ	norepinephrine	norepinephrine	norepinephrin	Y	O
reuptake	NN	reuptake	reuptake	reuptak	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nonsteroidal	JJ	nonsteroidal	nonsteroidal	nonsteroid	N	O
anti	NN	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
(	(	(	(	(	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
seeDrug	JJ	seedrug	seedrug	seedrug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.3	CD	7.3	7.3	7.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
loss	NN	loss	loss	loss	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
them	PRP	them	them	them	N	O
immediately	RB	immediately	immediately	immedi	N	O
or	CC	or	or	or	N	O
go	VB	go	go	go	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
emergency	NN	emergency	emergency	emerg	N	O
room	NN	room	room	room	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
pathological	JJ	pathological	pathological	patholog	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
established	JJ	established	established	establish	N	O
way	NN	way	way	way	N	O
to	TO	to	to	to	N	O
reverse	VB	reverse	reverse	revers	N	O
the	DT	the	the	the	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
persist	VB	persist	persist	persist	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
about	RB	about	about	about	N	O
two	CD	two	two	two	N	O
drug	NN	drug	drug	drug	N	O
half	NN	half	half	half	N	O
-	:	-	-	-	N	O
lives	NNS	lives	life	live	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
specific	JJ	specific	specific	specif	N	O
antidote	NN	antidote	antidote	antidot	N	O
for	IN	for	for	for	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

Hemodialysis	NN	hemodialysis	hemodialysis	hemodialysi	Y	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
appear	VB	appear	appear	appear	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
substantial	JJ	substantial	substantial	substanti	N	O
impact	NN	impact	impact	impact	N	O
on	IN	on	on	on	N	O
apixaban	JJ	apixaban	apixaban	apixaban	N	O
exposure	NN	exposure	exposure	exposur	N	O
[	NNP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Protamine	NNP	protamine	protamine	protamin	N	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
K	NNP	k	k	k	Y	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
affect	VB	affect	affect	affect	N	O
the	DT	the	the	the	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
antifibrinolytic	JJ	antifibrinolytic	antifibrinolytic	antifibrinolyt	N	O
agents	NNS	agents	agent	agent	N	O
(	(	(	(	(	N	O
tranexamic	JJ	tranexamic	tranexamic	tranexam	N	O
acid	NN	acid	acid	acid	N	O
,	,	,	,	,	N	O
aminocaproic	JJ	aminocaproic	aminocaproic	aminocapro	N	O
acid	NN	acid	acid	acid	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
individuals	NNS	individuals	individual	individu	N	O
receiving	VBG	receiving	receiving	receiv	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
neither	CC	neither	neither	neither	N	O
scientific	JJ	scientific	scientific	scientif	N	O
rationale	NN	rationale	rationale	rational	N	O
for	IN	for	for	for	N	O
reversal	JJ	reversal	reversal	revers	N	O
nor	CC	nor	nor	nor	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
systemic	JJ	systemic	systemic	system	N	O
hemostatics	NNS	hemostatics	hemostatics	hemostat	N	O
(	(	(	(	(	N	O
desmopressin	NN	desmopressin	desmopressin	desmopressin	N	O
and	CC	and	and	and	N	O
aprotinin	NN	aprotinin	aprotinin	aprotinin	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
individuals	NNS	individuals	individual	individu	N	O
receiving	VBG	receiving	receiving	receiv	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
procoagulant	JJ	procoagulant	procoagulant	procoagul	N	O
reversal	NN	reversal	reversal	revers	N	O
agents	NNS	agents	agent	agent	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
prothrombin	NN	prothrombin	prothrombin	prothrombin	Y	O
complex	JJ	complex	complex	complex	N	O
concentrate	NN	concentrate	concentrate	concentr	N	O
,	,	,	,	,	N	O
activated	VBD	activated	activated	activ	N	O
prothrombin	NN	prothrombin	prothrombin	prothrombin	Y	O
complex	JJ	complex	complex	complex	N	O
concentrate	NN	concentrate	concentrate	concentr	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
recombinant	JJ	recombinant	recombinant	recombin	N	O
factor	NN	factor	factor	factor	N	O
VIIa	NNP	viia	viia	viia	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
but	CC	but	but	but	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Activated	JJ	activated	activated	activ	N	O
oral	JJ	oral	oral	oral	N	O
charcoal	NN	charcoal	charcoal	charcoal	N	O
reduces	NNS	reduces	reduces	reduc	N	O
absorption	NN	absorption	absorption	absorpt	N	O
of	IN	of	of	of	N	O
apixaban	NN	apixaban	apixaban	apixaban	N	O
,	,	,	,	,	N	O
thereby	RB	thereby	thereby	therebi	N	O
lowering	VBG	lowering	lowering	lower	N	O
apixaban	JJ	apixaban	apixaban	apixaban	N	O
plasma	JJ	plasma	plasma	plasma	N	O
concentration	NN	concentration	concentration	concentr	N	O
[	NNP	[	[	[	N	O
seeOverdosage	NN	seeoverdosage	seeoverdosage	seeoverdosag	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Spinal	JJ	spinal	spinal	spinal	N	O
Epidural	NNP	epidural	epidural	epidur	N	O
Anesthesia	NNP	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
Puncture	NN	puncture	puncture	punctur	N	O

When	WRB	when	when	when	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
(	(	(	(	(	N	O
spinal	JJ	spinal	spinal	spinal	N	O
epidural	JJ	epidural	epidural	epidur	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
epidural	JJ	epidural	epidural	epidur	N	O
puncture	NN	puncture	puncture	punctur	N	O
is	VBZ	is	is	is	N	O
employed	VBN	employed	employed	employ	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antithrombotic	JJ	antithrombotic	antithrombotic	antithrombot	N	O
agents	NNS	agents	agent	agent	N	O
for	IN	for	for	for	N	O
prevention	NN	prevention	prevention	prevent	Y	O
of	IN	of	of	of	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
complications	NNS	complications	complication	complic	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
an	DT	an	an	an	N	O
epidural	JJ	epidural	epidural	epidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
term	NN	term	term	term	N	I-AdverseReaction
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
paralysis	NN	paralysis	paralysis	paralysi	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
increased	VBN	increased	increased	increas	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
postoperative	JJ	postoperative	postoperative	postop	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
indwelling	VBG	indwelling	indwelling	indwel	N	O
epidural	JJ	epidural	epidural	epidur	N	O
catheters	NNS	catheters	catheter	cathet	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
medicinal	JJ	medicinal	medicinal	medicin	N	O
products	NNS	products	product	product	N	O
affecting	VBG	affecting	affecting	affect	N	O
hemostasis	NN	hemostasis	hemostasis	hemostasi	Y	O
.	.	.	.	.	N	O

Indwelling	VBG	indwelling	indwelling	indwel	N	O
epidural	JJ	epidural	epidural	epidur	N	O
or	CC	or	or	or	N	O
intrathecal	JJ	intrathecal	intrathecal	intrathec	N	O
catheters	NNS	catheters	catheter	cathet	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
removed	VBN	removed	removed	remov	N	O
earlier	JJR	earlier	earlier	earlier	N	O
than	IN	than	than	than	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
earlier	JJR	earlier	earlier	earlier	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
removal	NN	removal	removal	remov	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
catheter	NN	catheter	catheter	cathet	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
increased	VBN	increased	increased	increas	N	O
by	IN	by	by	by	N	O
traumatic	JJ	traumatic	traumatic	traumat	N	O
or	CC	or	or	or	N	O
repeated	JJ	repeated	repeated	repeat	N	O
epidural	JJ	epidural	epidural	epidur	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
traumatic	JJ	traumatic	traumatic	traumat	N	O
puncture	NN	puncture	puncture	punctur	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
delay	VB	delay	delay	delay	N	O
the	DT	the	the	the	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
for	IN	for	for	for	N	O
48	CD	48	48	48	N	O
hours	NNS	hours	hour	hour	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
frequently	RB	frequently	frequently	frequent	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
numbness	JJ	numbness	numbness	numb	Y	O
or	CC	or	or	or	N	O
weakness	NN	weakness	weakness	weak	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
legs	NNS	legs	leg	leg	N	O
,	,	,	,	,	N	O
bowel	NN	bowel	bowel	bowel	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
bladder	VB	bladder	bladder	bladder	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
compromise	NN	compromise	compromise	compromis	N	O
is	VBZ	is	is	is	N	O
noted	VBN	noted	noted	note	N	O
,	,	,	,	,	N	O
urgent	JJ	urgent	urgent	urgent	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
necessary	JJ	necessary	necessary	necessari	N	O
.	.	.	.	.	N	O

Prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
intervention	NN	intervention	intervention	intervent	N	O
the	DT	the	the	the	N	O
physician	NN	physician	physician	physician	N	O
should	MD	should	should	should	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
benefit	NN	benefit	benefit	benefit	N	O
versus	IN	versus	versus	versu	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
in	IN	in	in	in	N	O
anticoagulated	JJ	anticoagulated	anticoagulated	anticoagul	N	O
patients	NNS	patients	patient	patient	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
anticoagulated	VBN	anticoagulated	anticoagulated	anticoagul	N	O
for	IN	for	for	for	N	O
thromboprophylaxis	NN	thromboprophylaxis	thromboprophylaxis	thromboprophylaxi	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Prosthetic	NNP	prosthetic	prosthetic	prosthet	N	O
Heart	NNP	heart	heart	heart	N	O
Valves	VBZ	valves	valve	valv	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
prosthetic	JJ	prosthetic	prosthetic	prosthet	N	O
heart	NN	heart	heart	heart	N	O
valves	NNS	valves	valve	valv	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Acute	NNP	acute	acute	acut	N	O
PE	NNP	pe	pe	pe	N	O
in	IN	in	in	in	N	O
Hemodynamically	NNP	hemodynamically	hemodynamically	hemodynam	N	O
Unstable	JJ	unstable	unstable	unstabl	N	O
Patients	NNS	patients	patient	patient	N	O
or	CC	or	or	or	N	O
Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
Require	VBP	require	require	requir	N	O
Thrombolysis	NNP	thrombolysis	thrombolysis	thrombolysi	Y	O
or	CC	or	or	or	N	O
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	O
Embolectomy	NNP	embolectomy	embolectomy	embolectomi	Y	O

Initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
ELIQUIS	NNP	eliquis	eliquis	eliqui	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
alternative	NN	alternative	alternative	altern	N	O
to	TO	to	to	to	N	O
unfractionated	JJ	unfractionated	unfractionated	unfraction	N	O
heparin	NN	heparin	heparin	heparin	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
PE	NNP	pe	pe	pe	N	O
who	WP	who	who	who	N	O
present	VBP	present	present	present	N	O
with	IN	with	with	with	N	O
hemodynamic	JJ	hemodynamic	hemodynamic	hemodynam	N	O
instability	NN	instability	instability	instabl	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
may	MD	may	may	may	N	O
receive	VB	receive	receive	receiv	N	O
thrombolysis	NN	thrombolysis	thrombolysis	thrombolysi	Y	O
or	CC	or	or	or	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
embolectomy	NN	embolectomy	embolectomy	embolectomi	Y	O
.	.	.	.	.	N	O

